Acorda Therapeutics Inc

-0.27 (-8.74%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)31.59M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$30.57 Million
Adjusted EPS-$1.56
See more estimates
10-Day MA$3.33
50-Day MA$4.12
200-Day MA$4.48
See more pivots

Acorda Therapeutics Inc Stock, NASDAQ:ACOR

420 Saw Mill River Road, Ardsley, New York 10502
Phone: +1.914.347.4300
Number of Employees: 168


Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.